Literature DB >> 16137927

Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors.

Manish Aghi1, E Antonio Chiocca.   

Abstract

Vessels are formed during embryonic development through three distinct processes. Angiogenesis and arteriogenesis involve the remodeling of established capillary networks and arterioles, while vasculogenesis involves the differentiation of mesodermal progenitor cells called angioblasts into mature endothelial cells. Until recently, postnatal vessel development was felt to occur exclusively through angiogenesis or arteriogenesis. However, recent studies using experimental tumor and ischemia models have raised controversy regarding whether vasculogenesis occurs in postnatal vessel development, with some studies suggesting the possibility and others refuting it. Here, we summarize the process of embryonic vessel development and review studies investigating the role of postnatal vasculogenesis in vessel formation in adult ischemia and tumors. We then focus on studies in which wild-type and genetically modified vascular progenitor cells have been investigated as possible cellular therapies for tumors or ischemia. We also take note of key issues that will need to be understood about the biology of vasculogenesis before cellular therapies utilizing vascular progenitor cells can be finally taken from the bench to the bedside.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16137927     DOI: 10.1016/j.ymthe.2005.07.693

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  31 in total

1.  Role of bone marrow-derived cells in angiogenesis: focus on macrophages and pericytes.

Authors:  Yanping Ding; Nan Song; Yongzhang Luo
Journal:  Cancer Microenviron       Date:  2012-04-20

Review 2.  Clinical implications of skeletal muscle blood-oxygenation-level-dependent (BOLD) MRI.

Authors:  Sasan Partovi; Sasan Karimi; Bjoern Jacobi; Anja-Carina Schulte; Markus Aschwanden; Lisa Zipp; John K Lyo; Christof Karmonik; Matthias Müller-Eschner; Rolf W Huegli; Georg Bongartz; Deniz Bilecen
Journal:  MAGMA       Date:  2012-02-29       Impact factor: 2.310

Review 3.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Jay K Kolls; Luis A Ortiz; Angela Panoskaltsis-Mortari; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2008-07-15

Review 4.  Inhibiting vasculogenesis after radiation: a new paradigm to improve local control by radiotherapy.

Authors:  Brown J Martin
Journal:  Semin Radiat Oncol       Date:  2013-10       Impact factor: 5.934

5.  Mesenchymal stem cells and their conditioned medium improve integration of purified induced pluripotent stem cell-derived cardiomyocyte clusters into myocardial tissue.

Authors:  Martin Rubach; Roland Adelmann; Moritz Haustein; Florian Drey; Kurt Pfannkuche; Bing Xiao; Annette Koester; Floris E A Udink ten Cate; Yeong-Hoon Choi; Klaus Neef; Azra Fatima; Tobias Hannes; Frank Pillekamp; Juergen Hescheler; Tomo Šarić; Konrad Brockmeier; Markus Khalil
Journal:  Stem Cells Dev       Date:  2014-01-15       Impact factor: 3.272

Review 6.  Biology of angiogenesis and invasion in glioma.

Authors:  Matthew C Tate; Manish K Aghi
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

7.  Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I.

Authors:  Maud Jost; Catherine Maillard; Julie Lecomte; Vincent Lambert; Marc Tjwa; Pierre Blaise; Maria-Luz Alvarez Gonzalez; Khalid Bajou; Silvia Blacher; Patrick Motte; Chantal Humblet; Marie Paule Defresne; Marc Thiry; Francis Frankenne; André Gothot; Peter Carmeliet; Jean-Marie Rakic; Jean-Michel Foidart; Agnès Noël
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

8.  Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

Authors:  Thomas R Coleman; Christof Westenfelder; Florian E Tögel; Ying Yang; Zhuma Hu; Leanne Swenson; Henri G D Leuvenink; Rutger J Ploeg; Livius V d'Uscio; Zvonimir S Katusic; Pietro Ghezzi; Adriana Zanetti; Kenneth Kaushansky; Norma E Fox; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

Review 9.  Anti-angiogenic gene therapy in the treatment of malignant gliomas.

Authors:  NaTosha N Gatson; E Antonio Chiocca; Balveen Kaur
Journal:  Neurosci Lett       Date:  2012-08-10       Impact factor: 3.046

10.  Incorporation of endothelial progenitor cells into the neovasculature of malignant glioma xenograft.

Authors:  Hua-rong Zhang; Fei-lan Chen; Chen-ping Xu; Yi-fang Ping; Qing-liang Wang; Zi-qing Liang; Ji Ming Wang; Xiu-wu Bian
Journal:  J Neurooncol       Date:  2008-12-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.